Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
IV Thrombolysis Does Not Improve Vision in Acute CRAO: Ahmed Koriesh on TenCRAOS Study
Ahmed Koriesh/LinkedIn
Jan 31, 2026, 16:35

IV Thrombolysis Does Not Improve Vision in Acute CRAO: Ahmed Koriesh on TenCRAOS Study

Ahmed Koriesh, Director Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:

”TenCRAOS — IV Thrombolysis Does Not Improve Vision in Acute CRAO

IV thrombolysis for central retinal artery occlusion (CRAO) has always been a debated topic.

Evidence has been limited — CRAO is uncommon, patients present late, and trials have been small. For years, we’ve had more questions than answers.

TenCRAOS (2026) randomized 78 patients with acute CRAO to IV tenecteplase (0.25 mg/kg) vs aspirin within 4.5 hours.

Key Findings:
Primary outcome: 20% TNK vs 24% aspirin (P = 0.69)
No visual benefit with IV thrombolysis

Safety signal: 1 fatal ICH; more SAEs with TNK (10 vs 4)

This is now the second negative RCT for IV thrombolysis in CRAO:

THEIA (2025): IV alteplase vs aspirin — no difference (66% vs 48%, P = 0.95)

What did guidelines say?

The AHA/ASA Scientific Statement (2021) on CRAO management stated that IV alteplase “may be considered” in carefully selected patients within 4.5 hours, with weak evidence (no RCT at that time) — this recommendation may need revisiting.

What about the AGILE meta-analysis?

The AGILE IPD meta-analysis (2025, N = 783) suggested early thrombolysis improves visual outcomes — but important caveats:

Pooled 35 studies, mostly single-arm observational studies — inherent selection bias

Subgroup of comparative studies was underpowered and could not reproduce the findings

Control group was heterogeneous (ocular massage, paracentesis, hemodilution, HBO, heparin) — not aspirin

However, AGILE did show potential benefit for intra-arterial thrombolysis (IAT) within 6 hours (OR 2.72 vs CST) — this still warrants RCT investigation.

Bottom Line:
IV thrombolysis for CRAO: RCT evidence is consistently negative — not recommended.
IA thrombolysis: Still under investigation.

AGILE suggests potential benefit within 6 hours, but RCT confirmation is needed.

So far, the evidence doesn’t support routine IV thrombolysis for acute CRAO.”

Stay updated on all scientific advances with Hemostasis Today.

AGILE AHA Ahmed Koriesh ASA Aspirin CRAO Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine TenCRAOS Tenecteplase Thrombolysis thrombosis
NewsFeed